ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Development of ursolic acid-loaded cubosomal nanocarriers: enhanced dissolution, pharmacokinetics, bioavailability, and anticancer activity.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ursolic acid (UA) is a promising anticancer agent whose therapeutic application is hindered by poor aqueous solubility, limited permeability, rapid elimination, and low oral bioavailability. In this study, UA-loaded cubosomal nanoparticles (UA-CN) were developed and optimized using a three-factor, three-level Box-Behnken design. The effects of glyceryl monooleate, Poloxamer 407, and microfluidization cycles on particle size, zeta potential, and entrapment efficiency were systematically evaluated. The optimized UA-CN exhibited a particle size of 131.9 ± 4.12 nm, zeta potential of - 44.2 ± 3.67 mV, and entrapment efficiency of 96.16 ± 1.89%. FTIR, XRD, and DSC analyses supported UA incorporation into the cubosomal matrix and a reduction in its crystalline character. In vitro dissolution studies demonstrated markedly enhanced drug release from UA-CN, with approximately 90% of UA released within 24 h compared with 38% from the pure drug. Pharmacokinetic evaluation in rabbits showed an approximately six-fold increase in oral bioavailability following UA-CN administration. The optimized cubosomal formulation also exhibited enhanced anticancer activity, supporting its potential to improve the biopharmaceutical performance of UA and its utility as a nanocarrier for breast cancer therapy.
Indexed as
Identifiers
42820989What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.